Episodios

  • Navigating the insurance maze with T1D with consultant (and D-Mom) Emily Adams

    Navigating the insurance maze with T1D with consultant (and D-Mom) Emily Adams
    Jul 16 2024

    This week, I think it’s fair to say that we all struggle with insurance issues. Diabetes – or any chronic condition – increases the hoops we jump through, the expense and the stress. I’m talking to Emily Adams an employee benefits consultant to get some advice about how to navigate. Emily thought she knew the system pretty well, but then her daughter was diagnosed with type 1 and she learned on a personal level how complex our system is.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Find out more about Moms' Night Out - registration is open for Denver and Philadelphia!

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Edgepark Medical Supplies

    Check out VIVI Cap to protect your insulin from extreme temperatures

    Drive research that matters through the T1D Exchange

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Twitter

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.
    Más Menos
    45 m
  • My son was diagnosed with T1D at age two. How was his first year away at college?

    My son was diagnosed with T1D at age two. How was his first year away at college?
    Jul 9 2024

    When my son was diagnosed with type 1 more than 17 years ago, the day he’d leave home seemed very far away, but also something we knew we needed to plan for. Well, Benny finished his Freshman year of college – he goes to school 300 miles away – and he’s here to talk about it. We answer your questions about how it went, how he managed, how I managed and what’s next.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Previous episodes with Benny

    Previous episodes with Lea

    Find out more about Moms' Night Out - registration is open for Denver and Philadelphia!

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Edgepark Medical Supplies

    Check out VIVI Cap to protect your insulin from extreme temperatures

    Drive research that matters through the T1D Exchange

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Twitter

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.
    Más Menos
    42 m
  • In the News... Generic GLP-1, All-in-one sensor and infusion set, 365-day CGM, T1D & Roblox and more!

    In the News... Generic GLP-1, All-in-one sensor and infusion set, 365-day CGM, T1D & Roblox and more!
    Jul 5 2024
    It’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The Eversense CGM could soon be approved for one year of continuous use, the first generic GLP-1 medication is launched, a new company tauts and all-in-one sensor and pump infusion set, a new diabetes accessory in the Roblox game, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX The first ever generic GLP-1 medication will soon be available in the US. It’s a generic of Victoza, originally approved by the FDA in 2010 for diabetes, is part of the same class of drugs that includes Ozempic and Mounjaro. Liraglutide is Glucagon-like peptide-1 receptor agonists (otherwise known as GLP-1s or GLP-1 RAs) are a class of incretin drugs that mimic the body’s natural hormones to help treat diabetes and obesity. However, the popularity of the drugs has spiraled out of control at times, leading to shortages and supply chain issues in the US and abroad. The arrival of a GLP-1 generic drug provides reasons to be hopeful for doctors and patients alike, but there are also caveats. Couple of caveats - liraglutide is injected once daily (vs. weekly) and many doctors say it doesn’t work as well for as many people as semaglutide and terzepatide. No confirmation on the price Two other generic options are being developed and could launch in December 2024. Patents for newer GLP-1 medications like Ozempic and Wegovy won’t expire until several years down the road https://www.healthline.com/health-news/victoza-generic-glp1-drug-available XX Senseonics plans to launch a 365-day sensor in the U.S. in the fourth quarter of this year. A one-year Eversense CGM could be a game changer for the company. In 2024, Senseonics expects to more than double U.S. new patient starts and increase the global installed base by around 50%. The growth is built on the current 180-day version of Senseonics’ implantable Eversense CGM. Eversense’s 180-day sensor can need calibrating twice a day, something Senseonics CEO Tim Goodnow said “has been a competitive disadvantage.” Users calibrate the 365-day sensor once a week. Senseonics is in talks with insulin pump manufacturers about integrating its Eversense CGM with their devices but has yet to commit to a timeline for finalizing an agreement. https://www.medtechdive.com/news/senseonics-365-day-cgm-2025-sales/719717/ XX People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. Still, doctors say it shouldn’t deter patients from using the medicines to treat diabetes or obesity. Last summer, doctors at Mass Eye and Ear noticed an unusually high number of patients with non-arteritic anterior ischemic optic neuropathy, or NAION, a type of eye stroke that causes sudden, painless vision loss in one eye. The condition is relatively rare — up to 10 out of 100,000 people in the general population may experience it — but the doctors noted three cases in one week, and each of those patients was taking semaglutide medications. The risk was found to be greatest within the first year of receiving a prescription for semaglutide. The study, published Wednesday in the medical journal JAMA Ophthalmology, cannot prove that semaglutide medications cause NAION. And the small number of patients — an average of about 100 cases were identified each year — from one specialized medical center may not apply to a broader population. The ways that semaglutides interact with the eyes are not entirely understood. And the exact cause of NAION is not known either. The condition causes damage to the optic nerve, but there is often no warning before vision loss. For now, patients who are taking semaglutide or considering treatment should discuss the risks and benefits with their doctors, especially ...
    Más Menos
    9 m
  • Dexcom updates from ADA 2024 with CEO Kevin Sayer

    Dexcom updates from ADA 2024 with CEO Kevin Sayer
    Jul 2 2024

    Stacey sits down with Dexcom’s CEO for an in-person interview at ADA Scientific Sessions. Dexcom made a little bit of news at the conference, but it’s a less-trumpeted replacement policy that had you all asking a lot of questions. We’ll go through the latest news, updates, sensor issues, and a peek into the future with Dexcom’s CEO Kevin Sayer.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Find out more about Moms' Night Out - registration is open for Denver and Philadelphia!

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Edgepark Medical Supplies

    Check out VIVI Cap to protect your insulin from extreme temperatures

    Drive research that matters through the T1D Exchange

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Twitter

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.com
    Más Menos
    37 m
  • What is EPI? DIY diabetes pioneer Dana Lewis wants you to know your risk

    What is EPI? DIY diabetes pioneer Dana Lewis wants you to know your risk
    Jun 25 2024

    DIY Pioneer Dana Lewis was diagnosed with something called EPI – exocrine pancreatic insufficiency a couple of years ago. She’d never heard of it and was shocked to find out diabetes is considered a common co-condition. In fact, 20-30 percent of people with diabetes can end up with EPI. EPI can cause a lot of discomfort and stomach issues – and health issues if left untreated. Of course, Dana jumped in, publishing a review of studies and now- creating studies of her own. She’ll explain what she’s doing, why she needs your help, and more about this condition that doesn’t get much attention.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Find your Exocrine Pancreatic Insufficiency Symptom Score using Dana Lewis's new tool: https://danamlewis.github.io/EPI-PEI-SS/

    Learn more from Dana here

    Find out more about Moms' Night Out - registration is open for Denver and Philadelphia!

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Edgepark Medical Supplies

    Check out VIVI Cap to protect your insulin from extreme temperatures

    Drive research that matters through the T1D Exchange

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Twitter

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.com
    Más Menos
    42 m
  • In the news.. Insulin pen shortage, Omnipod 5 update, once-weekly insulin approved in Canada, and more!

    In the news.. Insulin pen shortage, Omnipod 5 update, once-weekly insulin approved in Canada, and more!
    Jun 21 2024
    It’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: South Africa runs out of insulin pens - and why this could happen anywhere, once-weekly insulin is approved in Canada, update on Omnipod 5 with Dexcom G7 rollout, more older people are getting type 1 but more people are living longer with it, CGM at the Olympcs and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Quick note – the American Diabetes Association Scientific Sessions is this weekend. That means new research studies will be released, technology announced, and likely lots of news will be made. I’m recording this before the conference starts – if there’s enough going on we may have an additional In the News next week. XX Our top story right now… XX No more insulin pens for South Africa.. .as the pharmaceutical industry shifts production priorities to blockbuster weight-loss drugs. Novo Nordisk, the company that has supplied South Africa with human insulin in pens for a decade, opted not to renew its contract, which expired last month. No other company has bid on the contract — to supply 14 million pens for the next three years, at about $2 per pen. Novo Nordisk’s drugs Ozempic and Wegovy, which are widely prescribed in the U.S. for weight loss, are sold in single-use pens produced by many of the same contracted manufacturers who make the multidose insulin pens. A month’s supply of Ozempic in the United States costs about $1,000, far more than insulin. Novo Nordisk dominates the global market for insulin in pens and has supplied South Africa since 2014. Eli Lilly, the other major producer, has indicated in recent months that it is struggling to keep up with the significant demand for its weight-loss drug Zepbound. Novo Nordisk is continuing to supply human insulin in vials to South Africa, where more than four million people live with diabetes, but pens are considered much easier to use and more precise. The vial system was phased out for most South Africans in 2014. But recently, South Africa’s National Department of Health instructed clinicians that they should teach patients how to use vials and syringes of insulin instead of pens. I posted about this already and said this is a canary in the coal mine and everyone going to ADA should be asking Novo and Lilly about this. GLP medications are fantastic but insulin cannot be left behind. https://www.nytimes.com/2024/06/19/health/insulin-pens-south-africa-ozempic-wegovy.html XX Once a week basal insulin – for type 1 and type 2 – comes to Canada. Novo Nordisk announced that it’s version of insulin icodec will be available starting June 30th. They are calling it.. Awiqli – I promise I didn’t make that up. Canada is the first country to get the product. Awiqli works as a time release of insulin over the course of a week. It is more expensive. And Canada's Drug Agency, which assesses drugs and recommends whether they should qualify for reimbursement under public drug plans, is still doing the math here. No word on private insurers coverage yet. An FDA advisory board recently passed on approving weekly basal for people with type 1, saying the risk of low blood sugar was too great. But the full FDA hasn’t yet weighed in. https://www.ctvnews.ca/health/world-s-first-weekly-insulin-injection-coming-to-canada-in-2-weeks-manufacturer-says-1.6929321 XX The prevalence of people over 65 living with type 1 diabetes went up 180% in the past 30 years, a new study finds. That’s an increase of 1.3 million people over 65 in 1990 with the disease to 3.7 million in 2019, the authors noted in a study published on June 12 in The BMJ. Data included people from 204 countries and territories from 1990 to 2019. Dying from type 1 diabetes slipped by about 1% every year since 1990, the data also ...
    Más Menos
    8 m
  • The business of diabetes - Scott Strumello's perspective after 50 years of T1D

    The business of diabetes - Scott Strumello's perspective after 50 years of T1D
    Jun 18 2024

    Scott Strumello has lived almost 50 years with type 1. Diagnosed as a child in the 70s, he found the online community and started blogging. Scott has a unique perspective – with a background in finance and consulting, he’s a reliable source of what’s happening in earnings calls, legislation, and the business of diabetes. We have a great talk about what’s coming in terms of biosimilars, the role of PBMs and some legal action that may happen this year.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Stacey's webinar with Breakthrough T1D Mountain West Chapter

    The Breakthrough T1D announcement video

    Find out more about Moms' Night Out - registration is open for Denver and Philadelphia!

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Edgepark Medical Supplies

    Check out VIVI Cap to protect your insulin from extreme temperatures

    Learn more about AG1 from Athletic Greens

    Drive research that matters through the T1D Exchange

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Twitter

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.com
    Más Menos
    41 m
  • JDRF is now “Breakthrough T1D” - Behind the rebrand (and other changes)

    JDRF is now “Breakthrough T1D” - Behind the rebrand (and other changes)
    Jun 11 2024

    JDRF… is no more. A rebranding and name change means the organization founded in 1970 by concerned parents will now be known as Breakthrough T1D. You can guess some of the reasons for this change – the “J” for juvenile has long been a turn off for adults living with type 1 – but some of the other reasons are surprising. We’ll do a deep dive into what this means for the community, the fund raising and research, and the organization itself.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Stacey's webinar with Breakthrough T1D Mountain West Chapter

    The Breakthrough T1D announcement video

    Find out more about Moms' Night Out - registration is open for Denver and Philadelphia!

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Edgepark Medical Supplies

    Check out VIVI Cap to protect your insulin from extreme temperatures

    Learn more about AG1 from Athletic Greens

    Drive research that matters through the T1D Exchange

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Twitter

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.com
    Más Menos
    34 m